Vertex Pharmaceuticals Incorpor

Valuation Analysis

About the Company

Vertex Pharmaceuticals Incorpor en bref

Vertex Pharmaceuticals Incorpor (VRTX) is currently trading at 393,71 € with a market capitalization of 99,9 Md €. The trailing P/E ratio stands at 26.79x, with a forward P/E of 21.03x. The 52-week range spans from 316,01 € to 442,79 €; the current price is 11.1% below the yearly high. Year-over-year revenue growth stands at +7.8%. The net profit margin stands at 35.51%.

💰 Dividende

Vertex Pharmaceuticals Incorpor currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

29 analystes évaluent Vertex Pharmaceuticals Incorpor (VRTX) au consensus : Acheter. L'objectif de cours moyen est de 478,33 €, soit un potentiel de +21.49% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 287,68 € à 558,80 €.

Vertex Pharmaceuticals Incorpor : la thèse d'investissement en détail

Vertex Pharmaceuticals Incorpor (VRTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 61.4% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 54.39% gross margin and 38.13% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 35.51%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

À surveiller

• The forward P/E of 21.03x is meaningfully below the trailing 26.79x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 21.49% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Vertex Pharmaceuticals Incorpor?

Compare top-rated brokers — low fees, trusted providers, fully regulated.